IC
ORMP icon

Innealta Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Innealta Capital’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13
Closed -$33 – 1210
2024
Q2 		$33 Buy
+13
New +$31 ﹤0.01% 1776

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Innealta Capital's ORMP Position: Q3 2024 in Review

Innealta Capital sold out of Oramed Pharmaceuticals (ORMP) in Q3 2024, closing a stake of 13 shares — an estimated $33 sold.

Innealta Capital first reported a position in ORMP in Q2 2024 and held it in 1 quarter. The position peaked at $33 in Q2 2024. 55 funds tracked by Wall St. Rank hold ORMP as of Q3 2024.

  • Innealta Capital reported no remaining Oramed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 13 Oramed Pharmaceuticals shares in Q3 2024, an estimated $33.
  • Innealta Capital first reported a position in Oramed Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Oramed Pharmaceuticals position peaked at $33 in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.